KindlyMD (NASDAQ:NAKA) Releases Quarterly Earnings Results

KindlyMD (NASDAQ:NAKA) posted its quarterly earnings data on Thursday. The company reported ($6.65) earnings per share for the quarter, FiscalAI reports. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 55.86%. The firm had revenue of $35.87 million during the quarter.

KindlyMD Price Performance

KindlyMD stock traded down $0.12 during midday trading on Friday, hitting $4.93. 71,872 shares of the company were exchanged, compared to its average volume of 146,776. The company has a market cap of $85.78 million, a PE ratio of -0.14 and a beta of 15.95. KindlyMD has a fifty-two week low of $3.33 and a fifty-two week high of $624.00. The company’s fifty day moving average price is $4.39 and its 200-day moving average price is $7.56.

Insiders Place Their Bets

In other KindlyMD news, CEO David F. Bailey bought 55,115 shares of the stock in a transaction dated Thursday, May 28th. The stock was bought at an average cost of $5.62 per share, for a total transaction of $309,746.30. Following the completion of the purchase, the chief executive officer directly owned 3,175,476 shares of the company’s stock, valued at approximately $17,846,175.12. The trade was a 1.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have acquired 191,448 shares of company stock worth $992,908. 24.49% of the stock is currently owned by company insiders.

Institutional Trading of KindlyMD

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new stake in shares of KindlyMD during the 4th quarter valued at about $8,993,000. ParaFi Capital LP acquired a new stake in shares of KindlyMD during the 3rd quarter worth approximately $443,055,000. Hunting Hill Global Capital LLC acquired a new position in KindlyMD during the 4th quarter valued at approximately $4,672,000. Yorkville Advisors Global LP bought a new position in KindlyMD during the 4th quarter worth $3,265,000. Finally, UBS Group AG acquired a new stake in KindlyMD in the fourth quarter worth $2,958,000.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. TD Cowen raised their price objective on KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $22.33.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.